Home » PharmaEngine Prepares for Pancreatic Cancer Treatment Trial
PharmaEngine Prepares for Pancreatic Cancer Treatment Trial
PharmaEngine is preparing to launch a Phase II clinical trial using its PEP02 to treat patients with pancreatic cancer.
To begin next year in Taiwan and the U.S., the open-label trial will enroll patients with metastatic pancreatic cancer who have failed gemcitabine, a treatment used with chemotherapy.
The product is a liposome formulation of irinotecan. Irinotecan injection has been approved for the treatment of colorectal cancer and had sales of nearly $1 billion last year, the company said.
Upcoming Events
-
07May
-
14May
-
30May